Literature DB >> 33849933

GLP-1 Receptor Agonists in Diabetic Kidney Disease.

Erin D Michos1, Katherine R Tuttle2,3.   

Abstract

Entities:  

Keywords:  chronic diabetic complications; chronic kidney disease; diabetes mellitus; glucagon-like peptide-1 receptor

Mesh：

Substances：

Year:  2021        PMID： 33849933      PMCID： PMC8499005          DOI： 10.2215/CJN.18771220

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   10.614


× No keyword cloud information.
  9 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

2.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.

Authors:  Søren L Kristensen; Rasmus Rørth; Pardeep S Jhund; Kieran F Docherty; Naveed Sattar; David Preiss; Lars Køber; Mark C Petrie; John J V McMurray
Journal:  Lancet Diabetes Endocrinol       Date:  2019-08-14       Impact factor: 32.069

3.  Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline.

Authors:  Sankar D Navaneethan; Sophia Zoungas; M Luiza Caramori; Juliana C N Chan; Hiddo J L Heerspink; Clint Hurst; Adrian Liew; Erin D Michos; Wasiu A Olowu; Tami Sadusky; Nikhil Tandon; Katherine R Tuttle; Christoph Wanner; Katy G Wilkens; Lyubov Lytvyn; Jonathan C Craig; David J Tunnicliffe; Martin Howell; Marcello Tonelli; Michael Cheung; Amy Earley; Peter Rossing; Ian H de Boer; Kamlesh Khunti
Journal:  Ann Intern Med       Date:  2020-11-10       Impact factor: 25.391

4.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Jeffrey S Riesmeyer; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

5.  Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.

Authors:  Katherine R Tuttle; Mark C Lakshmanan; Brian Rayner; Robert S Busch; Alan G Zimmermann; D Bradley Woodward; Fady T Botros
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-14       Impact factor: 32.069

Review 6.  Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.

Authors:  Radica Z Alicic; Emily J Cox; Joshua J Neumiller; Katherine R Tuttle
Journal:  Nat Rev Nephrol       Date:  2020-11-20       Impact factor: 28.314

7.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Authors:  Adrian F Hernandez; Jennifer B Green; Salim Janmohamed; Ralph B D'Agostino; Christopher B Granger; Nigel P Jones; Lawrence A Leiter; Anne E Rosenberg; Kristina N Sigmon; Matthew C Somerville; Karl M Thorpe; John J V McMurray; Stefano Del Prato
Journal:  Lancet       Date:  2018-10-02       Impact factor: 79.321

8.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian
Journal:  J Am Coll Cardiol       Date:  2019-03-17       Impact factor: 24.094

9.  Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.

Authors:  Johannes F E Mann; Vivian Fonseca; Ofri Mosenzon; Itamar Raz; Bryan Goldman; Thomas Idorn; Bernt Johan von Scholten; Neil R Poulter
Journal:  Circulation       Date:  2018-12-18       Impact factor: 29.690
  9 in total
  1 in total

1.  Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.

Authors:  Jia-Jin Chen; Chao-Yi Wu; Chang-Chyi Jenq; Tao-Han Lee; Chung-Ying Tsai; Hui-Tzu Tu; Yu-Tung Huang; Chieh-Li Yen; Tzung-Hai Yen; Yung-Chang Chen; Ya-Chung Tian; Chih-Wei Yang; Huang-Yu Yang
Journal:  JAMA Netw Open       Date:  2022-03-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.